Saturday, May 6, 2023: 9:45 AM - 11:30 AM
Los Angeles Convention Center
Posted Room Name: 515A
Track
Adult Cardiac
103rd Annual Meeting
Presentations
Total Time: 15 Minutes
Speaker
*Jennifer Lawton, Johns Hopkins Univerity
-
Contact Me
Baltimore, MD
United States
Total Time: 15 Minutes
Objective: Females and patients with low socioeconomic status have poorer healthcare access with greater outcome inequities. We examined association of female sex and low socioeconomic status with rate of multiarterial grafting (MAG) during coronary artery bypass grafting (CABG) to advance quality for these priority populations.
Methods: Patients undergoing isolated CABG with two or more bypass grafts from 2011 to 2022 were evaluated in a statewide collaborative database. Patients with a history of mediastinal radiation, prior cardiac surgery, emergent/salvage status, and subclavian stenosis were excluded. Patients were stratified by the distressed community index (DCI) score, a socioeconomic ranking by zip code (scale of 0-100, 100 being the most distressed). Hierarchical regression modeling was performed to associate DCI and sex with MAG, incorporating patient factors (e.g., age, BMI, diabetes, creatinine) and surgery year, with hospital and surgeon as random effects.
Results: A total of 39,004 patients underwent CABG at 33 centers. The mean age was 66±10 years and 24% (n=9,388) were female. Compared to males, females lived in zip codes associated with higher median DCI (51 [IQR 24, 72] vs 42 [IQR 17, 66]), p<0.001). The overall rate of MAG was 15% and was lower among females (10% versus 17%, p<0.001). Overall adjusted odds of receiving MAG increased throughout the study period (2012 vs 2018, OR 0.20 [95% CI 0.17-0.22], p<0.001). After multivariable adjustment, females were less likely to receive MAG compared to males (OR 0.51 [95% CI 0.45-0.58], p<0.001) (Figure). Similarly, patients living in zip codes with a higher DCI score had lower adjusted odds of receiving MAG (OR 0.90 per 10-point increase [95% CI 0.87-0.94], p<0.001). There was no association between Black race (vs White race) and MAG (OR 0.88 [95% CI 0.76-1.02] p=0.24). The impact of DCI and sex on MAG did not change by surgery-year (p>0.05) suggesting these effects did not change over time.
Conclusions: After risk adjustment, females are half as likely to undergo MAG during CABG than males. Similarly, patients from low socioeconomic status are less likely to receive MAG, even after accounting for risk and hospital. These disparity gaps persisted even though the overall rate of MAG increased over time. Increased attention to identify and address barriers to MAG in these populations is required to provide more equitable surgical revascularization practices.
View Submission
Invited Discussant
*Marc Ruel, University of Ottawa Heart Institute
-
Contact Me
Ottawa, ON
Canada
Abstract Presenter
Catherine Wagner, Michigan Medicine
-
Contact Me
Ann Arbor, MI
United States
Total Time: 15 Minutes
Background: Patients on ticagrelor undergoing urgent cardiac surgery are at high risk for perioperative bleeding complications. We measured ticagrelor levels before and after cardiopulmonary bypass (CPB) to determine whether intraoperative hemoadsorption can actively remove ticagrelor in patients undergoing urgent cardiac surgery.
Methods: The hemoadsorption cartridge was incorporated in the CPB circuit and remained active for the duration of the pump run. Blood samples were collected before and after CPB. The main objective of the current analysis was to compare mean total plasma ticagrelor levels (ng/mL) at baseline with ticagrelor levels obtained at the end of CPB. Plasma ticagrelor levels were measured at a certified outside laboratory (Altascience, Laval, QC, Canada). Data are presented as mean ± SD.
Results: A total of 11 patients undergoing urgent CABG at 3 institutions were included (mean age 67.9±9.8 years, 91% male, mean EuroSCORE-II of 3.0±3.3% (range: 0.7-12.4%). Mean intraoperative hemoadsorption duration was 97.1±43.4min with a mean flow rate through the device of 422.9±40.3mL/min. Mean ticagrelor levels pre-CPB were 103.5±63.8ng/mL compared with mean post-CPB levels of 34.0±17.5ng/ml, representing a highly significant 67.1% reduction (P<0.001, Figure). Sites reported that the intraoperative integration of the device was simple and safe without any device-related adverse events reported.
Conclusions: This is the first in vivo report demonstrating that intraoperative hemoadsorption can efficiently remove ticagrelor and significantly reduce circulating drug levels. Whether active ticagrelor removal can reduce serious perioperative bleeding in patients undergoing urgent cardiac surgery is currently evaluated in the double blind, randomized Safe and Timely Antithrombotic Removal – Ticagrelor (STAR-T) trial.
View Submission
Invited Discussant
*Mario Gaudino, Weill Cornell Medicine/NYP Hospital
-
Contact Me
New York, NY
United States
Abstract Presenter
Michael Schmoeckel, Asklepios Klinik St. Georg
-
Contact Me
Hamburg, Germany
United States
Total Time: 15 Minutes
Objective: Due to lack of supportive data, tricuspid regurgitation (TR) is usually not addressed for patient undergoing coronary artery bypass grafting (CABG). Here we evaluate changes in degree of TR over time and its impact on survival in patient undergoing CABG.
Methods: We reviewed data of 10183 patients who underwent isolated CABG between January 2000 and January 2021. Patients were stratified by severity of preoperative TR and divided into two groups: non-significant TR (none-trivial, mild) and significant TR (moderate, severe). We excluded patients who had undergone previous tricuspid valve surgery and underwent concomitant valve or ablative surgery. Propensity score matching and Cox proportional hazards models were used to determine association between grade of TR and the primary endpoint of all-cause mortality. The secondary endpoint was the change of TR severity on postoperative echocardiography.
Results: After propensity score matching, 826 patients were identified (413 in each group). At baseline, 290 (70.2%) and 123 (29.8%) patients had none-trivial and mild TR in non-significant TR group, respectively. Similarly, 388 (93.9%) and 25 (6.1%) patients had moderate and severe TR in significant TR group, respectively. On postoperative echo TR improved in 6.3% of patient in the non-significant group and 25.7% in the significant group (Figure 1). The Kaplan-Meier survival curve demonstrated a significant survival difference between patient with preoperative non-significant and significant TR (p < 0.001). But after adjusting for significant confounders (age, sex, preoperative diabetes mellitus, preoperative atrial fibrillation, left ventricular function and pulmonary artery systolic pressure), the significant TR group did not show any worse survival as compared to the non-significant group (HR 1.13; 95% CI, 0.88-1.5; p = 0.38). While age (HR 1.05; 95% CI, 1.03-1.1; p < 0.001), preoperative diabetes mellitus (HR 1.74; 95% CI, 1.38-2.2; p < 0.001), and pulmonary artery systolic pressure (HR 1.01; 95% CI, 1.00-1.02; p = 0.009) were significantly associated with increased risk of mortality.
Conclusions: Significant (moderate or severe) preoperative TR improves in 25.7% patient after isolated CABG, while non-significant (trace or mild) TR can worsen in 39.7%. But more importantly after adjusting for other factors significant TR does not seem to affect long-term survival after isolated CABG.
View Submission
Invited Discussant
♦Patrick Myers, CHUV
-
Contact Me
Lausanne, -
Switzerland
Abstract Presenter
Daisuke Kaneyuki, NewYork- Presbyterian/Columbia University Medical Center
-
Contact Me
Greensburg, PA
United States
Total Time: 15 Minutes
Objective: The differential effects of COVID-19 active viral infection, viral convalescence, and altered care processes on emergency CABG (eCABG) outcomes have not been studied. We sought to evaluate whether the altered processes of care due to the pandemic's burden on healthcare institutions negatively impacted eCABG outcomes.
Methods: The National COVID Cohort Collaborative (N3C) contains clinical observation, lab, medication, and procedural data from 6.5 million COVID+ (15.9 million total) patients from 76 US centers. We queried N3C (Feb. 2020 to Aug. 2022; Concept ID 4336464) to include adult patients undergoing eCABG. Patients were divided into 3 groups according to COVID test results: negative result (C-Neg), positive result <2 weeks before CABG (C-Active), or positive result >2 weeks before CABG (C-Conv). The National Surgical Quality Improvement Program (NSQIP) database was utilized for pre-COVID controls from 2016-2018. Propensity matching was performed using inverse probability of treatment weighting based on: age, gender, comorbidity score, race, social determinants of health and COVID status. Statistical analysis was performed using standardized mean difference, t-test and Chi-square test.
Results: In N3C, 16,757 patients underwent eCABG (16,262 C-Neg, 125 C-Active, 370 C-Conv); there were 546 eCABG in NSQIP pre-COVID group (Table 1). The incidence of hospital mortality, 30-day mortality, infectious complications, and renal impairment were significantly higher in C-Active compared to C-Neg and C-Conv. Compared to pre-COVID, C-Active had increased hospital and 30-day mortality. CVA and bleeding complications did not differ. After propensity matching, length of stay (LOS) (OR 1.5), in-hospital death (OR 2.3), death within 30 and 90 days of discharge (OR 3.8, 3.8), renal impairment (OR 1.1), infectious complications (OR 3.4) and pneumonia (OR 3.8) were significantly greater in C-Active compared to C-Neg. Compared to C-Conv, C-Active had increased LOS (OR 2.7) and incidence of death (OR 6.1).
Conclusions: Traditional processes of care were altered during the COVID-19 pandemic. We conclude that eCABG in C-Active patients is associated with significantly increased mortality, LOS, and renal and infectious morbidity. Equivalent mortality in C-Neg and pre-COVID patients indicates that COVID associated changes in processes of care did not impact eCABG outcomes. Additional research into optimal timing of eCABG after COVID positivity is warranted.
View Submission
Invited Discussant
*Rakesh Arora, Cleveland University Hospitals
-
Contact Me
Cleveland, OH
United States
Abstract Presenter
Emily Grimsley, University of South Florida
-
Contact Me
Tampa, FL
United States
Total Time: 15 Minutes
Objective: We aimed to explore optimal patient selection and perioperative mechanical circulatory support (MCS) in patients with reduced ejection fraction (EF) who undergo surgical revascularization.
Methods: Patients with reduced EF (<35%) undergoing isolated coronary artery bypass grafting (CABG) from 2015-2021 were identified. Requirement of preoperative MCS (pre-MCS) and postoperative MCS (post-MCS) were noted, defined as use of intra-aortic balloon pump (IABP), ECMO, or Impella. Primary outcomes of interest were in-hospital mortality and long-term survival. Logistic regression was used to identify risk factors for MCS requirement.
Results: A total of 378 patients were included. Median STS predicted risk of mortality was 2.4% (IQR 1.3-4.4%). Sixty-five percent (n=246) of patients had previous myocardial infarction, of which 75% were within 21 days of CABG. Twenty-one patients (5.5%) presented in cardiogenic shock, of which 15 were in shock at the time of CABG. Thirty-nine patients (10.3%) required pre-MCS; compared to patients that did not require pre-MCS, those that did had lower pulmonary artery saturation (57.8% vs 63%, p=0.01) and cardiac index (2.0 vs 2.5, p=0.01) on preop catheterization and lower LV end diastolic diameter (50mm vs 55mm, p=0.01) on echo. Of patients that required pre-MCS, 8 (20.5%) required post-MCS (2 IABP, 4 ECMO, 1 Impella, 1 Centrimag). Of patients that did not require pre-MCS, 22 (6.4%) required post-MCS (14 IABP, 5 ECMO, 3 Impella). Independent risk factors for requiring post-MCS were low preop EF (OR 0.91, 95%CI 0.85-0.99, p=0.02), presence of mild MR compared to no MR preop (OR 3.37, 95%CI 1.17-9.73, p=0.03), and cross-clamp time (OR 1.02, 95%CI 1.01-1.04, p=0.02). Overall, in-hospital mortality was 2.9% and 3-year survival was 95.2%. Compared to those who did not require perioperative MCS, those that required pre-MCS had similar in-hospital mortality (3.2% vs 1.6%, p=.50) and 3-year survival (96.8% vs 96.8%, p=.98). However, patients who required post-MCS had significantly worse in-hospital mortality and 3-year survival (16.7% and 76.7% respectively, p <0.001).
Conclusion: In a large series of patients with reduced EF who underwent surgical revascularization, we report favorable outcomes with selective use of MCS. Despite worse severity of illness, patients requiring pre-MCS have similar outcomes to those that do not require perioperative MCS, while patients requiring post-MCS have worse short- and long-term survival.
View Submission
Invited Discussant
*Leora Yarboro, University of Virginia
-
Contact Me
Charlottesville, VA
United States
Abstract Presenter
Alice Vinogradsky, Columbia University
-
Contact Me
New York City, NY
United States
Total Time: 15 Minutes
Speaker
*Stephen Fremes, MD, MSc, Division of Cardiac Surgery, University of Toronto
-
Contact Me
Toronto, ON
Canada